Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.

Tournigand, Christophe; Samson, Benoit; Scheithauer, Werner; Lledo, Gérard; Viret, F.; Thewis, André; Ramée, Jean François; Tubiana-Mathieu, Nicole; Dauba, Jérôme; Dupuis, Olivier; Rinaldi, Yves; Mabro, May; Aucoin, Nathalie; Khalil, Ahmed; Latreille, Jean; Louvet, Christophe; Brusquant, David; Bonnetain, Franck; Chibaudel, Benoist; Gramont, Aimery de

doi:10.1200/jco.2012.30.15_suppl.lba3500

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following systemic chemotherapy, the metastatic tumors regressed in a proportion of the patients. A number of clinical studies ( 18 , 19 ) support the use of capecitabine as maintenance therapy, as it has been shown to prolong PFS, but provides no OS benefit. It is recommended that such patients receive a local, minimally invasive treatment to achieve TFS.…”

Section: Discussionmentioning

confidence: 99%

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer

Zhao

Shi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

With the development of systemic chemotherapy, the survival time of patients with advanced colorectal cancer (CRC) has increased. In addition, local treatments, such as microwave ablation and radioactive seed implantation, have been shown to be effective. However, the number of studies reporting on the effect of systemic chemotherapy combined with local treatments is limited. The present study was conducted to determine the effect of local treatment combined with systemic chemotherapy in patients with initial unresectable metastatic CRC (mCRC). Clinicopathological and follow-up data from 273 patients with initial unresectable mCRC between April, 2007 and October, 2013 were retrospectively analyzed. A total of 51 patients received minimally invasive treatments combined with systemic chemotherapy and 39 patients achieved tumor-free survival (TFS). The median TFS time was 9 months (range, 2–45 months); the median overall survival (OS) time was 40 months (range, 12–108 months). In patients who did not achieve TFS, the OS was 37 months. Thus, patients who achieved TFS exhibited a significantly longer OS compared with those who did not achieve TFS (P=0.049). The results of the univariate analysis demonstrated that certain characteristics, such as the number of lesions and maximum tumor diameter, were associated with the achievement of TFS. The patients assessed herein achieved TFS in response to local treatments combined with systemic chemotherapy. Furthermore, the achieved TFS provided an OS benefit.

show abstract

Section: Discussionmentioning

confidence: 99%

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer

Zhao

Shi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…This study of 90 patients noted a favorable PFS of 13.6 months (95% CI: 10.2-15.8 months) with maintenance bevacizumab and erlotinib. To verify these findings, the Phase III GERCOR DREAM trial randomized 446 mCRC patients previously treated with FOLFOX, XELOX or FOLFIRI regimens plus bevacizumab to maintenance therapy with bevacizumab 7.5 mg/kg every 3 weeks alone or bevacizumab 7.5 mg/kg every 3 weeks plus erlotinib 150 mg per day continuously [53]. Median maintenance therapy PFS was longer in the bevacizumab plus erlotinib arm (5.9 vs 4.8 months; HR: 0.76; 95% CI: 0.61-0.94; p = 0.01); no difference in OS was seen.…”

Section: Maintenance Therapy With Biologics In Mcrcmentioning

confidence: 99%

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer

Ciombor

Goldberg

2014

Hepatic Oncol.

View full text Add to dashboard Cite

With the advent of new drugs and therapeutic combinations for metastatic colorectal cancer, the prognosis for this often incurable disease is improving. In addition to traditional cytotoxic chemotherapeutics, targeted biologic therapies, such as cetuximab, panitumumab, bevacizumab, aflibercept and regorafenib, are significantly impacting the treatment of this disease. Recent investigations have focused on determination of the optimal usage of these biologic therapies, but many controversies still exist. Specifically, emerging data regarding appropriate combinations of cytotoxics and biologics in each metastatic colorectal cancer treatment setting, the superiority of particular biologics as single agents or in combination with chemotherapy, dual biologic therapy, use of biologics for conversion or maintenance therapies, and predictive biomarker discovery for biologics are addressed in this article, as these issues are rapidly changing our approach to the treatment of the patient with metastatic colorectal cancer.

show abstract

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.

Cited by 2 publications

References 0 publications

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer

Contact Info

Product

Resources

About